Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD

ClinicalTrials.gov ID: NCT03282123

Public ClinicalTrials.gov record NCT03282123. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Multi-Site Phase 2 Study of the Safety and Effect of Manualized MDMA-Assisted Therapy for the Treatment of Severe Posttraumatic Stress Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD. The main question it aims to answer is: Do three open-label sessions of MDMA-assisted therapy reduce PTSD symptoms? Participants will receive three non-drug preparatory sessions followed by three sessions of MDMA-assisted therapy. Each MDMA-assisted therapy session is followed by three non-drug integrative therapy sessions.

Study identification

NCT ID
NCT03282123
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Resilient Pharmaceuticals
Industry
Enrollment
38 participants

Conditions and interventions

Conditions

Interventions

Drug · Behavioral

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 15, 2017
Primary completion
Aug 9, 2019
Completion
Aug 9, 2019
Last update posted
Jun 4, 2025

2017 – 2019

United States locations

U.S. sites
12
U.S. states
8
U.S. cities
10
Facility City State ZIP Site status
New School Research LLC North Hollywood California 91601
San Francisco Insight and Integration Center San Francisco California 94114
University of California San Francisco San Francisco California 94122
Aguazul-Blue Water Inc. Boulder Colorado 80302
Wholeness Center Fort Collins Colorado 80525
University of Connecticut Farmington Connecticut 06030
Ray Worthy Psychiatry LLC New Orleans Louisiana 70123
Trauma Research Foundation Brookline Massachusetts 02446
New York University New York New York 10016
Affective Care New York New York 10024
Zen Therapeutic Solutions, LLC Mt. Pleasant South Carolina 29464
University of Wisconsin at Madison Madison Wisconsin 53705

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03282123, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 4, 2025 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03282123 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →